Clinical Trials

/Clinical Trials

GIST Updates from the ASCO Annual Meeting 2018

Executive Director, Norman Scherzer, and Real World Evidence Data Scientist, Dr. Yu Wang, of the Life Raft Group recently attended the ASCO (American Society of Clinical Oncologists) 2018 meeting in Chicago. Dr. Wang describes [...]

By | 2018-07-05T20:42:52+00:00 June 18th, 2018|Clinical Trials, News, Research|

Deciphera Pharmaceuticals Announces the Start of Phase 3 Clinical Trial with DCC-2618 in GIST

On January 4th, 2018 Deciphera Pharmaceuticals, Inc, announced the start of the Phase 3 INVICTUS trial. This randomized trial is for 4th line GIST patients that have failed (or are intolerant) the [...]

By | 2018-06-13T09:30:09+00:00 January 9th, 2018|Clinical Trials, News|

It’s a Journey: Our Experience on Clinical Trials

By Jennifer Moore, LRG MemberI was waiting in line to pick up a new prescription for Gleevec when my husband ran in and told me to forget it. After two surgeries, a year on 400 [...]

By | 2018-07-30T10:26:09+00:00 December 28th, 2017|Clinical Trials, Member Stories, News, Newsletter|

Why Do Cancer Patients Join Clinical Trials?

At the most basic level, cancer patients join clinical trials because of perceived value and perceived cost. In this context, perceived cost refers to more than just financial cost, although that is important. Perceived cost [...]

By | 2018-06-19T15:14:09+00:00 December 28th, 2017|Clinical Trials, News, Newsletter|

GIST Patient Community Update on BLU-285 Clinical Program

Dr. Anthony Boral, Chief Medical Officer of Blueprint Medicines, provided an update on the clinical development of BLU-285, an investigational medicine being developed for patients with advanced GIST. The presentation included an update on [...]

By | 2018-07-18T09:42:26+00:00 July 6th, 2017|Clinical Trials, Webcast|

Loxo Oncology Announces Plans for LOXO-101

In a recent press release, Loxo Oncology announced an update on the status of their TRK (tropomyosin receptor kinase) inhibitor drug, larotrectinib (LOXO-101). Larotrectinib targets the NTRK genes, which encode for the TRK kinases. These [...]

By | 2018-08-01T14:55:44+00:00 December 22nd, 2016|Clinical Trials, News, Research|

Quadruple-Negative GIST Tumors May Be More Likely To Harbor NF1 Mutations As Well

In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]

By | 2018-08-01T11:55:43+00:00 July 19th, 2016|Clinical Trials, News, Research|

Recent Posts

Upcoming Events

  1. Michigan GDOL 2018

    Michigan GDOL 2018

    October 27 @ 8:00 AM - 3:00 PM
  2. NTFC

    Night to Fight Cancer

    November 7 @ 6:00 PM - 11:00 PM